

In the claims:

Please cancel Claims 1-20 and 22-25 without prejudice as being directed to a non-elected invention.

Please amend the claims as follows.

Db 26. (amended) A method of modifying the sensitivity of cells containing stem cell factor receptors to a chemotherapeutic agent comprising administering a monoclonal antibody, or fragment thereof, which binds to an epitope on a receptor recognized by human stem cell factor in an amount sufficient to inhibit binding of stem cell factor to the receptor or to decrease the growth or development of receptor-containing cells, thereby modifying the sensitivity of the cells to the chemotherapeutic agent.